Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 18,356Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/06/30/3107872/0/en/Crinetics-to-Showcase-the-Next-Generation-of-Endocrinology-Innovation-at-ENDO-2025-with-Eight-Presentations-From-its-Deep-Pipeline.html

GLOBENEWSWIRE
30 Jun 2025

https://www.globenewswire.com/news-release/2025/03/27/3050988/0/en/Crinetics-Pharmaceuticals-Announces-European-Medicines-Agency-EMA-Validation-of-Marketing-Authorization-Application-MAA-and-Orphan-Drug-Designation-ODD-for-Paltusotine-in-Acromegal.html

GLOBENEWSWIRE
27 Mar 2025

https://www.globenewswire.com/news-release/2024/12/09/2993693/0/en/Crinetics-Announces-FDA-Acceptance-of-New-Drug-Application-for-Paltusotine-for-Adult-Patients-with-Acromegaly.html

GLOBENEWSWIRE
09 Dec 2024

https://www.globenewswire.com/news-release/2024/09/26/2954138/0/en/Crinetics-Submits-New-Drug-Application-for-Paltusotine-for-the-Treatment-of-Acromegaly.html

GLOBENEWSWIRE
26 Sep 2024

https://www.globenewswire.com/news-release/2024/06/03/2892444/0/en/Crinetics-Presents-New-Data-at-ENDO-2024-that-Increases-Body-of-Evidence-Positioning-Once-Daily-Oral-Paltusotine-as-Potential-First-Choice-Treatment-Option-for-Acromegaly.html

GLOBENEWSWIRE
03 Jun 2024

https://www.globenewswire.com/news-release/2024/05/08/2878214/0/en/Crinetics-Pharmaceuticals-to-Present-Advancements-from-Atumelnant-CRN04894-and-Paltusotine-Development-Programs-at-ENDO-2024.html

GLOBENEWSWIRE
08 May 2024